ClinicalTrials.Veeva

Menu

Impact of Immune Status on Secondary Infections in Patients With Acute Respiratory Failure

Charité University Medicine Berlin logo

Charité University Medicine Berlin

Status

Enrolling

Conditions

ARDS

Study type

Observational

Funder types

Other

Identifiers

NCT06511622
ARDS-Infectio

Details and patient eligibility

About

This is a retrospective observational study over the period 1/2019 - 02/2024 with the aim of identifying patients with a predisposition to secondary infections.

Full description

As a reference center, Charité Universitaetsmedizin Berlin has been treating patients with the most severe form of acute respiratory failure, known as acute respiratory distress syndrome (ARDS), for more than 30 years. Despite lung-protective forms of ventilation and the use of extracorporeal procedures for oxygenation and decarboxylation (ECMO), mortality is around forty percent. In addition to the primary cause of ARDS, further infectious complications often develop during the course of the disease, which delay recovery.

The aim of this study is to investigate infectious complications (ventilator-associated pneumonia, reactivation of Herpes viridae, pathogen resistance despite formally correct therapy, fungal infections) depending on the immune status.

Enrollment

200 estimated patients

Sex

All

Ages

7+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male and female acute respiratory distress syndrome patients who had an immune status within 48 h of admission
  • Patients who received intensive care treatment for acute respiratory distress syndrome ward 8i at Charité in the period from 01/2019 to 02/2024 with a maximum follow-up period of 90 days

Exclusion criteria

  • None

Trial contacts and locations

1

Loading...

Central trial contact

Claudia Spies, MD, Prof.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems